SynthesisEBioMedicine2023

Mendelian randomization and clinical trial evidence supports TYK2 inhibition as a therapeutic target for autoimmune diseases.

Shuai Yuan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.